CANC vs FTXH
Tema Oncology ETF against First Trust Nasdaq Pharmaceuticals ETF: cost, size, returns, what they hold and how much of it is the same.
Overlap by weight
25%
12 shared positions
Fee gap
15 bp
FTXH is cheaper
1-year return gap
4.5 pts
FTXH is ahead
Larger fund
FTXH
$1.1B
Side by side
| CANC | FTXH | |
|---|---|---|
| Fund | Tema Oncology ETF | First Trust Nasdaq Pharmaceuticals ETF |
| Issuer | Tema | First Trust |
| Category | Biotech & Health Innovation | Health Care |
| Expense ratio | 0.75% | 0.60% |
| Assets | $203M | $1.1B |
| Average daily dollar volume | $1.3M | $10M |
| Listed | Aug 14, 2023 | Sep 20, 2016 |
| FrenzyCap score | 36 | 51 |
| 1-month return | −2.4% | +1.8% |
| 3-month return | −0.4% | +7.9% |
| Year to date | +17.5% | +25.3% |
| 1-year return | +36.2% | +40.7% |
| 30-day volatility | 21.4% | 15.2% |
| Worst drawdown, 1 year | −11.3% | −7.5% |
| Trailing 12-month yield | 0.05% | 0.70% |
| Holdings | 57 | 51 |
| Top 10 weight | 42.9% | 53.1% |
| Look-through P/E | — | 43.5 |
| Holdings vs fair value | +5.0% | +7.5% |
| Holdings above 200-day average | 61% | 83% |
| Net flow, latest 3 reported months | +$14M thru May 2026 | +$3.3M thru Jun 2026 |
| 30-day implied volatility | — | 37.9% |
| Holdings as of | as of May 31, 2026SEC filing | as of Jun 30, 2026SEC filing |
Returns are price returns and exclude distributions. Flows are each fund's own latest reported months and may not cover the same period.
Largest shared holdings
27% of CANC · 49% of FTXH
Sector mix of the stock holdings
| Sector | CANC | FTXH | Gap |
|---|---|---|---|
| Health Care | 84.5% | 92.7% | −8.2% |
| Technology | 0.0% | 2.8% | −2.8% |
More: full overlap table · CANC holdings · FTXH holdings
Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.